# Reparixin in COVID-19 Pneumonia - Efficacy and Safety

> **NCT04794803** · PHASE2,PHASE3 · TERMINATED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 56 (actual)

## Conditions studied

- Severe Pneumonia

## Interventions

- **DRUG:** Reparixin
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT04794803
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-05
- **Primary completion:** 2020-11-27
- **Final completion:** 2021-02-02
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** The sponsor has decided to start with a separate protocol for phase 3 and therefore this study was terminated with only phase 2.
- **Last updated:** 2024-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04794803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04794803, "Reparixin in COVID-19 Pneumonia - Efficacy and Safety". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04794803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*